-
Real Time Chart
-
Stock Profile
-
Stock Fundamentals
Financials As Reported
-
accession Number
0001682852-23-000021
-
accounts Payable Current
389,000,000
-
accounts Receivable Net Current
1,113,000,000
-
accumulated Other Comprehensive Income Loss Net Of Tax
--267,000,000
-
allocated Share Based Compensation Expense
75,000,000
-
amendment Flag
false
-
assets
24,125,000,000
-
assets Current
12,122,000,000
-
available For Sale Securities Debt Maturities Single Maturity Date
1970-05-30
-
cash And Cash Equivalents At Carrying Value
3,441,000,000
-
cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
3,461,000,000
-
cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
244,000,000
-
cik
1,682,852
-
city Area Code
617
-
common Stock Par Or Stated Value Per Share
0.0001
-
common Stock Shares Authorized
1,600,000,000
-
common Stock Shares Issued
384,000,000
-
common Stock Shares Outstanding
384,000,000
-
comprehensive Income Net Of Tax
182,000,000
-
contract With Customer Liability
1,892,000,000
-
contract With Customer Liability Current
1,219,000,000
-
cost Of Goods And Services Sold
792,000,000
-
current Fiscal Year End Date
--12-31
-
date Filed
2023-05-04
-
depreciation Depletion And Amortization
78,000,000
-
document Fiscal Period Focus
Q1
-
document Fiscal Year Focus
2,023
-
document Period End Date
2023-03-31
-
document Transition Report
false
-
document Type
10-Q
-
earnings Per Share Basic
0.2
-
earnings Per Share Diluted
0.19
-
effective Income Tax Rate Continuing Operations
1.259
-
employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
789,000,000
-
employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1
P3Y2M12D
-
entity Address Address Line 1
200 Technology Square
-
entity Address City Or Town
Cambridge,
-
entity Address Postal Zip Code
2,139
-
entity Address State Or Province
MA
-
entity Central Index Key
1,682,852
-
entity Current Reporting Status
Yes
-
entity Emerging Growth Company
false
-
entity File Number
001-38753
-
entity Filer Category
Large Accelerated Filer
-
entity Incorporation State Country Code
DE
-
entity Interactive Data Current
Yes
-
entity Name
Moderna, Inc.
-
entity Registrant Name
Moderna, Inc.
-
entity Shell Company
false
-
entity Small Business
false
-
entity Tax Identification Number
81-3467528
-
finance Lease Liability
984,000,000
-
finance Lease Liability Current
153,000,000
-
finance Lease Liability Current Statement Of Financial Position Extensible List
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
-
finance Lease Liability Noncurrent
831,000,000
-
finance Lease Liability Payments Due
1,637,000,000
-
finance Lease Liability Payments Due Next Twelve Months
128,000,000
-
finance Lease Liability Payments Due Year Four
23,000,000
-
finance Lease Liability Payments Due Year Three
107,000,000
-
finance Lease Liability Payments Due Year Two
128,000,000
-
finance Lease Liability Undiscounted Excess Amount
653,000,000
-
finance Lease Right Of Use Asset
1,033,000,000
-
income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
--305,000,000
-
income Tax Expense Benefit
--384,000,000
-
increase Decrease In Accounts Payable
--117,000,000
-
increase Decrease In Accounts Receivable
--272,000,000
-
increase Decrease In Contract With Customer Liability
--819,000,000
-
increase Decrease In Inventories
--216,000,000
-
increase Decrease In Other Operating Liabilities
--15,000,000
-
inventory Net
732,000,000
-
irs Number
813,467,528
-
lessee Operating Lease Liability Payments Due
159,000,000
-
lessee Operating Lease Liability Payments Due Next Twelve Months
23,000,000
-
lessee Operating Lease Liability Payments Due Year Four
19,000,000
-
lessee Operating Lease Liability Payments Due Year Three
18,000,000
-
lessee Operating Lease Liability Payments Due Year Two
20,000,000
-
lessee Operating Lease Liability Undiscounted Excess Amount
35,000,000
-
liabilities
5,262,000,000
-
liabilities And Stockholders Equity
24,125,000,000
-
liabilities Current
3,499,000,000
-
local Phone Number
714-6500
-
net Cash Provided By Used In Financing Activities
--542,000,000
-
net Cash Provided By Used In Investing Activities
2,011,000,000
-
net Cash Provided By Used In Operating Activities
--1,225,000,000
-
net Income Loss
79,000,000
-
operatingand Finance Lease Liability
1,108,000,000
-
operatingand Finance Lease Rightof Use Asset
1,150,000,000
-
operating Income Loss
--366,000,000
-
operating Lease Liability
124,000,000
-
operating Lease Liability Current
28,000,000
-
operating Lease Liability Current Statement Of Financial Position Extensible List
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
-
operating Lease Liability Noncurrent
96,000,000
-
operating Lease Right Of Use Asset
117,000,000
-
other Assets Current
64,000,000
-
other Assets Noncurrent
1,164,000,000
-
other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
103,000,000
-
other Comprehensive Income Loss Reclassification Adjustment From AOCI For Sale Of Securities Net Of Tax
--16,000,000
-
other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
79,000,000
-
other Liabilities Current
212,000,000
-
other Liabilities Noncurrent
163,000,000
-
other Noncash Income Expense
4,000,000
-
other Nonoperating Income Expense
--48,000,000
-
payments For Repurchase Of Common Stock
526,000,000
-
payments To Acquire Available For Sale Securities Debt
1,085,000,000
-
payments To Acquire Businesses Net Of Cash Acquired
85,000,000
-
payments To Acquire Property Plant And Equipment
113,000,000
-
period End
1,680,220,800,000
-
period Start
1,672,531,200,000
-
proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
1,360,000,000
-
proceeds From Sale Of Available For Sale Securities Debt
1,957,000,000
-
report Link
https://www.sec.gov/Archives/edgar/data/1682852/000168285223000021/mrna-20230331_htm.xml
-
research And Development Expense
1,131,000,000
-
retained Earnings Accumulated Deficit
18,399,000,000
-
share Based Compensation
75,000,000
-
stockholders Equity
18,863,000,000
-
trading Symbol
MRNA
-
update
1970-01-01
-
weighted Average Number Diluted Shares Outstanding Adjustment
19,000,000
-
weighted Average Number Of Diluted Shares Outstanding
405,000,000
-
weighted Average Number Of Shares Outstanding Basic
386,000,000
-
id
REPORTED_FINANCIALS
-
key
MRNA
-
subkey
10-Q
-
date
2023-05-04
-
updated
2023-05-05
-
Symbol Info
-
Symbol Over View
-
Technical Analysis
MRNA stock fundamentals - financials as reported